Peg-interferon alpha-2b    (DrugBank: Interferon alpha-2B)

1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis    [ 120 clinical trials,   182 drugs,   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways]
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 120 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00846430
(ClinicalTrials.gov)
October 200816/1/2009Medical Treatment of High-Risk NeurofibromasMedical Treatment of High-Risk Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical TherapiesNeurofibromatosis 1Drug: Peg-Interferon alpha-2b;Drug: Celecoxib (Celebrex);Drug: Temozolomide (temodar);Drug: Vincristine Sulfate (Oncovin)Spectrum Health HospitalsNULLActive, not recruiting2 Years30 YearsBoth20Phase 2United States